Tag - Sean Lavin

Markets

Analysts slash Neuronetics PTs but maintain buy ratings

Analysts for Canaccord Genuity and BTIG slashed their prices targets for Neuronetics (NASDAQ:STIM) but maintained their “buy” ratings after the company reported that third quarter results missed consensus estimates...

November 6, 2019

Markets

BTIG cuts Obalon Therapeutics PT to $7 from $13

BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...

March 6, 2018

Tag - Sean Lavin

Analysts slash Neuronetics PTs but maintain buy ratings

BTIG cuts Obalon Therapeutics PT to $7 from $13

General

More